ARGENX SE is 8.3x more valuable than Immunovant, Inc. by market capitalization ($53.35 B vs $6.40 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IMVT | ARGX |
|---|---|---|
| Market cap | $6.40 B | $53.35 B |
| US-listed rank | #1219 | #306 |
| Net income (latest FY) | -$505.61M | - |
| SEC filings | 611 | 272 |
ARGENX SE is 8.3x more valuable than Immunovant, Inc. by market capitalization ($53.35 B vs $6.40 B).
Full pages: Immunovant, Inc. and ARGENX SE, or browse the full rankings.